Digoxin is a cardiac glycoside used for the treatment of certain heart conditions, primarily congestive heart failure and atrial fibrillation. It works by inhibiting the sodium-potassium ATPase pump, which increases intracellular calcium in cardiac cells and enhances myocardial contractility (positive inotropy), while also exerting vagomimetic effects to slow the heart rate.
It is derived from the Digitalis lanata plant and is administered orally or intravenously, depending on the clinical scenario.
Indications include:
• Heart failure (especially in patients with reduced ejection fraction)
• Atrial fibrillation (to control ventricular rate)
• Sometimes used in supraventricular tachyarrhythmias
Parent: Digoxin
Parent: Digoxin
Impurities in digoxin may arise from its extraction from natural sources, semi-synthetic modification, or degradation during storage. Due to its narrow therapeutic index, controlling impurities is critical and regulated under ICH Q3A/B, USP, and EP standards.
Process-Related Impurities
• Other cardiac glycosides from Digitalis species (e.g., gitoxin, digitoxin)
• Incomplete deglycosylated forms or aglycones
• Residual solvents from plant extraction or crystallization, such as ethanol or methanol
Degradation Impurities
• Deglycosylated forms (removal of sugar moieties)
• Oxidation products of the steroid nucleus
• Impurities formed under acidic, basic, or photolytic conditions
• Loss of lactone ring integrity (essential for bioactivity)
Elemental Impurities
• Trace metals such as iron, copper, or zinc from processing equipment
• Strictly controlled under ICH Q3D, especially for parenteral use
Analytical Techniques for Impurity Detection
• High-Performance Liquid Chromatography (HPLC) – for identification and quantification of digoxin and related glycosides
• LC-MS/MS (Liquid Chromatography–Tandem Mass Spectrometry) – for structural elucidation of unknown impurities
• Thin-Layer Chromatography (TLC) – for fingerprinting and identity testing of Digitalis extracts
• Gas Chromatography (GC) – for residual solvent determination
• ICP-MS – for elemental impurity profiling
Digoxin is used to treat heart failure and atrial fibrillation by improving the force of heart contraction and controlling heart rate.
It inhibits the Na⁺/K⁺-ATPase pump, leading to increased intracellular calcium in cardiac cells, enhancing contractility, and promoting vagal tone to reduce heart rate.
• Nausea, vomiting
• Fatigue, dizziness
• Visual disturbances (yellow or blurred vision)
• Bradycardia or arrhythmias (especially with overdose)
• Requires regular monitoring of blood levels
Yes, but due to its narrow therapeutic window, patients must be monitored closely for toxicity, especially if renal function is impaired or electrolyte levels fluctuate.
Digoxin is sensitive to heat, light, and pH extremes. It should be stored in airtight, light-resistant containers at controlled room temperature, and aqueous solutions should be used promptly.
